Jill Andersen Sells 30,706 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 30,706 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $25,793.04. Following the transaction, the insider owned 283,774 shares of the company’s stock, valued at $238,370.16. This trade represents a 9.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Monday, August 17th, Jill Andersen sold 37,256 shares of Invivyd stock. The shares were sold at an average price of $0.72, for a total transaction of $26,824.32.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.96 on Thursday. The firm’s 50-day moving average is $0.77 and its two-hundred day moving average is $1.23. The company has a market capitalization of $282.82 million, a PE ratio of -2.91 and a beta of 0.71. Invivyd, Inc. has a 12-month low of $0.48 and a 12-month high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The business had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. On average, analysts forecast that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. increased its stake in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC boosted its stake in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after buying an additional 391,617 shares during the last quarter. Marshall Wace LLP acquired a new stake in Invivyd in the 2nd quarter worth about $158,000. Jane Street Group LLC purchased a new stake in Invivyd in the 2nd quarter valued at about $147,000. Finally, Vanguard Group Inc. grew its holdings in Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after buying an additional 1,834,970 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Wall Street Analysts Forecast Growth

IVVD has been the subject of a number of recent research reports. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Finally, BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.